clinical trial · NCT07537881
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
RemeGen Co., Ltd.·phase2·not yet recruiting·n = 326
Solid TumorsRC288 For InjectionRC288 For Injection
brief summary
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
started
Apr 30, 2026
primary completion
Dec 30, 2029
completion
Jun 30, 2030
last updated
Apr 17, 2026
official title
A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC288 for Injection in the Treatment of Locally Advanced Unresectable or Metastatic Malignant Solid Tumor.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol